Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CEFD | 17.31 | 0.08 | +0.46% |
| ETRACS Monthly Pay 1.5X Leveraged Closed-End Fund Index ETN (CEFD) | |||
| GUG | 14.08 | 0.04 | +0.28% |
| Guggenheim Active Allocation Fund | |||
| ZJUN | 27.71 | -0.01 | -0.02% |
| Innovator Equity Defined Protection ETF - 1 Yr June (ZJUN) | |||
| FHLC | 88.06 | -0.18 | -0.20% |
| Fidelity MSCI Health Care Index ETF (FHLC) | |||
| HYUP | 39.06 | -0.08 | -0.22% |
| Xtrackers High Beta High Yield Bond ETF (HYUP) | |||
A.I.dvisor indicates that over the last year, RNAC has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To RNAC | 1D Price Change % | ||
|---|---|---|---|---|
| RNAC | 100% | +1.10% | ||
| TAOX - RNAC | 91% Closely correlated | +6.56% | ||
| PALI - RNAC | 81% Closely correlated | +9.82% | ||
| EDIT - RNAC | 46% Loosely correlated | +1.17% | ||
| NKTX - RNAC | 44% Loosely correlated | +0.66% | ||
| LXEO - RNAC | 42% Loosely correlated | +1.63% | ||
More | ||||
a developer of targeted immunotherapies and vaccines to treat and prevent diseases
Industry Biotechnology
RNAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 44 cases where RNAC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RNAC's RSI Indicator exited the oversold zone, 35 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on RNAC as a result. In 68 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for RNAC just turned positive on October 21, 2026. Looking at past instances where RNAC's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNAC advanced for three days, in 218 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 50 cases where RNAC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The 50-day moving average for RNAC moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RNAC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.549) is normal, around the industry mean (3.051). P/E Ratio (-1.109) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (144.928) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. RNAC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.